Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report
Low-grade serous ovarian cancer represents a minority of ovarian cancers and has distinctive features from high grade epithelial ovarian cancer. While less aggressive, in advanced stage they can be poorly chemo-responsive and incur a treatment challenge. Next generation sequencing of tumors has allo...
Saved in:
Main Authors: | Miriam Champer (Author), Devin Miller (Author), Dennis Yi-Shin Kuo (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2019-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation
by: Bárbara Lima, et al.
Published: (2022) -
Response to trametinib, hydroxychloroquine, and bevacizumab in a young woman with NRAS-mutated metastatic intrahepatic cholangiocarcinoma: a case report
by: Aram A. Musaelyan, et al.
Published: (2024) -
Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation
by: Alberto A. Mendivil, et al.
Published: (2018) -
Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer
by: Shashank Sama, et al.
Published: (2024) -
Proteome profiling of low grade serous ovarian cancer
by: Haniyeh Bashi zadeh fakhar, et al.
Published: (2019)